UroGen Pharma Ltd. — Director's Dealing 2020

Dec 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-12-04

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-04	Ordinary Shares	M	1042	—	Acquired	20385	Direct
2020-12-04	Ordinary Shares	S	662	$19.85	Disposed	19723	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-04	Restricted Stock Units	$	M	1042	Disposed		Ordinary Shares (1042)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.